Are Systemic Inflammation Response Index and Systemic Immune-Inflammation Index an ideal biomarker for epileptic patients?

This is the authors' abstract. We don't add key points for this paper.

Background and Purpose inflammation is considered responsible for the pathogenesis of epilepsy. Inflammation plays a pivotal role in epilepsy.Various inflammatory markers are known related to epilepsy. No study has yet investigated the relationship between epilepsy and systemic inflammation response index (SIRI) and systemic immune-inflammation index (SII). This study aimed to evaluate the systemic inflammation response index (SIRI) and systemic immune-inflammation index (SII) in epilepsy. Methods This study included patients with epilepsy who presented to the neurology department within last five years. Results The epileptic group included 110 patients (63 males, 47 females) and the control group included 65 healthy individuals (33 males, 32 females). The mean age of the epilepsy (n = 110) and healthy control group (n = 65) was 33.0 ± 14.0 and 34.0 ± 10.2 years, respectively. SII and SIRI levels were 603.0 ± 469,6 and 1,42 ± 1,08 in the epileptic group and 567.6 ± 218.9 and 1,16 ± 0,58 in the control group. There were no significant differences between two groups (p > 0.05). Conclusion Our study results suggest that although is an associated with inflammation, SII and SIRI are still not an ideal biomarker for epileptic patients. This study is important because it investigated SII and SIRI in patients with epilepsy for the first time. Further prospective studies involving a larger sample size should be performed to have more valuable results for interpretation.